Pk - Merz solution for infusion 500ml, 2 fl.

Parkinson's disease, parkinson's syndrome (akinetic crisis, acute decompensation).
Violation of vigilance (initiative) in the post-comatose period.
Herpes zoster neuralgia.

Intravenously. 1-2 times a day, 500 ml; the dose can be increased up to 3 times a day, 500 ml. The duration of the infusion is 3 hours (55 drops per minute). The average duration of therapy for neuralgia with herpes zoster is 1 week, followed by a switch to oral administration of the drug.

each 500 ml bottle of solution for infusion contains:
200 mg of the active substance amaptadine sulfate (1-adamantanamine sulfate).
excipients: sodium chloride 4500 mg, water for injection up to 500 ml.

Hypersensitivity to any component of the drug; severe congestive heart failure (class IV according to the New York Heart Association), cardiomyopathy, myocarditis, atrioventricular block II and III degree, bradycardia with a heart rate of less than 55 beats / min, prolongation of the QT interval of more than 420 ms, ventricular arrhythmia (including the number of ventricular flutter); pregnancy and the period of breastfeeding; low blood levels of potassium and magnesium; simultaneous administration with drugs that lengthen the QT interval; severe renal failure (creatinine clearance less than 10 ml / min), childhood.

Carefully

Prostatic hyperplasia, narrow-angle glaucoma, renal failure of varying severity (there is a risk of drug accumulation), agitation, delirium, depression of the central nervous system, exogenous psychosis (including a history), coadministration with memantine, triamterene / hydrochlorothiazide.

Tradename:

PC-Merz

International non-proprietary name:

amantadine

Dosage form:

solution for infusion

Composition: each 500 ml bottle of solution for infusion contains:
200 mg of the active substance amaptadine sulfate (1-adamantanamine sulfate).
excipients: sodium chloride 4500 mg, water for injection up to 500 ml.

Description : colorless, transparent solution.

Pharmacotherapeutic group:

antiparkinsonian drug

ATX code : N04BB01.

Pharmacological properties

Pharmacodynamics:
Amantadine has an indirect agonistic effect on striatal dopamine receptors. Increases the extracellular concentration of dopamine by both intensifying its production and blocking the reuptake of dopamine by presynaptic neurons. At therapeutic concentrations, amantadine slows down the production of acetylcholine and thus has an anticholinergic effect.

Pharmacokinetics:
The average plasma concentration of amantadine sulfate after its infusion in an amount of 200 mg for 3 hours is 0.54 ?l. At a dosage of 200 mg per day, the average plasma concentration by the end of the administration of the 6th day of treatment is 0.76 ?l. The total ground clearance is 3.6 l / h; the half-life is from 10 to 30 hours, with an average of about 10 hours. Amantadine is about 67% bound to blood plasma proteins. Penetrates the blood-brain barrier. Excreted by the kidneys practically unchanged (90% of a single dose); a small amount is excreted in feces. Dialysis is ineffective (about 5% per procedure).

Indications for use

Parkinson's disease, parkinson's syndrome (akinetic crisis, acute decompensation).
Violation of vigilance (initiative) in the post-comatose period.
Herpes zoster neuralgia.

Contraindications

Hypersensitivity to any component of the drug; severe congestive heart failure (class IV according to the New York Heart Association), cardiomyopathy, myocarditis, atrioventricular block II and III degree, bradycardia with a heart rate of less than 55 beats / min, prolongation of the QT interval of more than 420 ms, ventricular arrhythmia (including the number of ventricular flutter); pregnancy and the period of breastfeeding; low blood levels of potassium and magnesium; simultaneous administration with drugs that lengthen the QT interval; severe renal failure (creatinine clearance less than 10 ml / min), childhood.

Carefully

Prostatic hyperplasia, narrow-angle glaucoma, renal failure of varying severity (there is a risk of drug accumulation), agitation, delirium, depression of the central nervous system, exogenous psychosis (including a history), coadministration with memantine, triamterene / hydrochlorothiazide.

Method of administration and dosage

Intravenously. 1-2 times a day, 500 ml; the dose can be increased up to 3 times a day, 500 ml. The duration of the infusion is 3 hours (55 drops per minute). The average duration of therapy for neuralgia with herpes zoster is 1 week, followed by a switch to oral administration of the drug.

Overdose

Symptoms: nausea, vomiting, tremors, ataxia, decreased visual acuity, lethargy, dysarthria, depression, epileptic seizures, cardiac arrhythmia. Symptomatic treatment (the use of sedatives, anticonvulsants and antiarrhythmic drugs).

Interaction with other medicinal products

The simultaneous administration of amantadine and drugs that cause an increase in the OT interval is contraindicated, in particular:
- some class 1 A antiarrhythmic drugs (for example, kinidine, disopyramide, procainamide), and class III (for example, amiodarone and sotalol);
- some antipsychotic drugs (for example, thioridazine, chlorpromazine, pimozide);
- some tricyclic and tetracyclic antidepressants (for example, amitriptyline);
- some antihistamines (for example, astemizole, terfenadine);
- some macrolide antibiotics (for example, erythromycin, clarithromycin);
- some gyrase inhibitors (for example, sparfloxasin);
- antifungal agents of the azole group, and other drugs, in particular, bidupine, halofantrine, co-trimoxazole, pentamidine, cisapride and bepridil.
Simultaneous administration of diuretics, which are a combination of triamterene / hydrochlorothiazide, can lead to an increase in the concentration of amantadine in plasma.
When taken simultaneously with other antiparkinsonian drugs (such as levodopa, bromocriptine, memantine, trihexyphenidil), it may be necessary to reduce the dose of the simultaneously taken drug, or both drugs to avoid undesirable consequences, in particular, psychotic reactions.
Anticholinergics, sympathomimetics, and memantine: Increase side effects.
Drugs that stimulate the central nervous system (including psychostimulants), ethanol increase the risk of side effects.

special instructions

Treatment with PK-Merz should not be stopped suddenly, as this can lead to worsening of symptoms. Patients suffering from cardiovascular diseases should be under constant medical supervision when prescribing PK-Merz. Alcohol intake is contraindicated during treatment. Use with caution during work for drivers of vehicles and people whose profession is associated with increased concentration of attention.

Release form

Solution for infusion 200 mg / 500 ml. 500 ml in a bottle made of polymer material, equipped with a special fixture. The bottle is hermetically sealed with a polymer material lid. Aluminum foil is applied to the top of the lid. 1 or 2 bottles are placed in a cardboard box with instructions for use.

Shelf life

5 years. Do not use after the expiration date.

Conditions of dispensing from pharmacies

On prescription.